The NA-ATTC has launched an Advanced Therapy Medicinal Product (ATMP) Cost Model which supports NHS institutions to assess finance and resource implications arising from the adoption of an ATMP into clinical practice. This resource is accompanied by a comprehensive guide to ensure operators are aware how to use it.
The model captures a range of potential activities across an ATMP clinical pathway and is broadly based on the current commissioned CAR-Ts and associated suite of activities. The model allows the user to define the level of usage of resources which will auto populate the costs and generates an overall cost and resource impact summary.
Wider applications of the tool are envisioned as NHS institutions can build assumptions into the model to support a business case for ATMP services and outputs from the model can be used to develop an ATMP Strategy for Trusts and Boards.
